Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients

Kumar, Deepali; Campbell, Patricia; Höschler, Katja; Hidalgo, Luis; Al-Dabbagh, Mona; Wilson, Leticia; Humar, Atul

doi:10.1097/tp.0000000000000861

Cited by 63 publications

(70 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…According to previous studies, the immunogenicity of influenza vaccine is reduced in SOT recipients, with up to 15-70% of patients failing to respond to the vaccine, depending on the organ transplanted, the immunosuppressive regimen, and the time of vaccination after transplant [29][30][31][32][33]. In our study, previous administration of induction therapy had no impact on the influenza vaccine response (humoral and cellular) even though the CD4+ cell count was lower in the group that had received ATG.…”

Section: Discussionmentioning

confidence: 51%

Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies

Héquet

Pascual

Lartey

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 51%

Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies

Héquet

Pascual

Lartey

et al. 2016

Vaccine

Self Cite

View full text Add to dashboard Cite

“…The major findings of our study were as follows: (1) for influenza A, which is comparable with seroconversion rates after influenza vaccination in this population. [35][36][37][38][39] In addition, the poor HI antibody response in transplant recipients has important methodologic implications for epidemiologic studies. The fact that there is a hyporesponsive subpopulation among transplant recipients, which does not develop HI antibodies in response to influenza vaccination or to natural infection explains the difficulties that have been experienced so far in finding clearly superior alternative vaccine strategies compared to the standard vaccine.…”

Section: Discussionmentioning

confidence: 99%

Humoral response to natural influenza infection in solid organ transplant recipients

Hirzel

Ferreira

L'Huillier

et al. 2019

American Journal of Transplantation

Self Cite

View full text Add to dashboard Cite

The humoral immune response of transplant recipients to influenza vaccination has been studied in detail. In contrast, the hemagglutinin inhibiting (HI) antibody response evoked by natural influenza infection and its impact on viral kinetics is unknown. In this prospective, multicenter, cohort study of natural influenza infection in transplant recipients, we measured HI antibody titers at presentation and 4 weeks later. Serial nasopharyngeal viral loads were determined using a quantitative influenza A polymerase chain reaction (PCR). We analyzed 196 transplant recipients with influenza infection. In the cohort of organ transplant patients with influenza A (n = 116), seropositivity rates for strain‐specific antibodies were 44.0% (95% confidence interval [CI] 31.5‐53.2%) at diagnosis and 64.7% (95% CI 55.4‐72.9%) 4 weeks postinfection. Seroconversion was observed in 32.8% (95% CI 24.7‐41.9%) of the cases. Lung transplant recipients were more likely to seroconvert (P = .002) and vaccine recipients were less likely to seroconvert (P = .024). A subset of patients (n = 30) who were unresponsive to prior vaccination were also unresponsive to natural infection. There was no correlation between viral kinetics and antibody response. This study provides novel data on the seroresponse to influenza infection in transplant patients and its relationship to a number of parameters including a prior vaccination status, virologic measures, and clinical variables.

show abstract

“…A randomized trial of MF59-adjuvanted influenza vaccine in kidney transplants showed that this vaccine had similar immunogenicity to unadjuvanted vaccine. In this study, persons aged C 65 years had significantly diminished vaccine immunogenicity; after this group was excluded from the analysis, a subgroup analysis of patients aged 18-65 years showed that the adjuvanted vaccine performed better than standard vaccine [82]. In adult allogeneic HSCT patients, another randomized control trial using MF59, done by Natori et al, also found that adjuvanted vaccine demonstrated similar immunogenicity to non-adjuvanted vaccine [83].…”

Section: Influenza Vaccinementioning

confidence: 60%

Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management

Law

Kumar

2017

Drugs Aging

Self Cite

View full text Add to dashboard Cite

Organ and stem cell transplantation has been one of the greatest advances in modern medicine, and is the primary treatment modality for many end-stage diseases. As our population ages, so do the transplant recipients, and with that comes many new challenges. Respiratory viruses have been a large contributor to the mortality and morbidity of solid organ transplant (SOT) and hematopoietic stem cell transplant (HSCT) recipients. Respiratory viruses are generally a long-term complication of transplantation and primarily acquired in the community. With the emergence of molecular methods, newer respiratory viruses are being detected. Respiratory viruses appear to cause severe disease in the older transplant population. Influenza vaccine remains the mainstay of prevention in transplant recipients, although immunogenicity of current vaccines is suboptimal. Limited therapies are available for other respiratory viruses. The next decade will likely bring newer antivirals and vaccines to the forefront. Our goal is to provide the most up to date knowledge of respiratory viral infections in our aging transplant population.

show abstract

Randomized Controlled Trial of Adjuvanted Versus Nonadjuvanted Influenza Vaccine in Kidney Transplant Recipients

Abstract: Adjuvanted vaccine was safe and had similar immunogenicity to standard vaccine in the overall transplant cohort but did show a potential immunogenicity benefit for the 18 to 64 years age group.

Cited by 63 publications

References 35 publications

Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies

Humoral, T-cell and B-cell immune responses to seasonal influenza vaccine in solid organ transplant recipients receiving anti-T cell therapies

Humoral response to natural influenza infection in solid organ transplant recipients

Post-transplant Viral Respiratory Infections in the Older Patient: Epidemiology, Diagnosis, and Management

Contact Info

Product

Resources

About